STOCK TITAN

Benitec Biopharma quarterly loss widens to $12.9M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Benitec Biopharma Inc. (BNTC) reported a net loss of $12.925 million for the three months ended September 30, 2026, versus $8.965 million a year earlier. Total operating expenses were $14.477 million, including $8.618 million in research and development and $5.859 million in general and administrative expenses. Loss per share was $0.26 versus $0.22, and cash and cash equivalents were $176.368 million at quarter-end.

Interim BB-301 Phase 1b/2a results showed a 100% responder rate across all Cohort 1 low-dose and Cohort 2 high-dose patients; no serious adverse events had been reported in any patient treated to date. Benitec said it remains on track to begin the pivotal trial in mid-2027, with study design to be finalized in the first calendar quarter of 2027.

The board approved moving the fiscal year-end from June 30 to December 31, effective November 12, 2026. A transition report will cover July 1 through December 31, 2026, followed by calendar-year reporting beginning with the year ending December 31, 2027.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • Minor point100% responder rate reported across BB-301 Cohorts 1 and 2.

Negative

  • Moderate pointNet loss was $12.925 million, versus $8.965 million a year earlier.

Filing Explained

Common shares issued and outstanding rose from June 30, 2026’s 34,416,834 to September 30, 2026’s 34,889,313; this larger share base reduces the proportional ownership of holders whose share counts stayed unchanged.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Cash and cash equivalents $176.368 million As of September 30, 2026
Total operating expenses $14.477 million Three months ended September 30, 2026; $9.803 million in the comparable 2025 quarter
Research and development expenses $8.618 million Three months ended September 30, 2026; $3.370 million in the comparable 2025 quarter
General and administrative expenses $5.859 million Three months ended September 30, 2026; $6.433 million in the comparable 2025 quarter
Net loss $12.925 million Three months ended September 30, 2026; $8.965 million in the comparable 2025 quarter
Net loss per share ($0.26) per share Three months ended September 30, 2026; ($0.22) per share in the comparable 2025 quarter
BB-301 responder rate 100% Reported across all Cohort 1 low-dose and Cohort 2 high-dose patients
Pivotal trial timing Mid-2027 Benitec said it remains on track to begin the trial
ddRNAi technical
"DNA-directed RNA interference (ddRNAi) platform"
AAV9 capsid medical
"a novel, modified AAV9 capsid"
AAV9 capsid is the protein shell of adeno-associated virus serotype 9 used to package and deliver genetic material in gene therapy. The capsid controls which tissues the vector naturally targets, how the immune system recognizes it, and how easy it is to manufacture and scale. For investors, those properties affect a therapy’s potential market reach, development complexity, safety profile, and regulatory considerations—like choosing the right delivery truck for a specific cargo and route.
siRNAs medical
"two small inhibitory RNAs (siRNAs)"
Small interfering RNAs (siRNAs) are short strands of genetic material designed to bind and silence specific genes, like sending a targeted "mute" command to a particular instruction in a cell. Investors care because siRNA-based therapies can precisely treat diseases by turning off harmful genes, offering potential for strong clinical benefits and revenue but also carrying scientific, regulatory and manufacturing risks that affect a biotech company’s value.
Orphan Drug Designation regulatory
"received Orphan Drug Designation from the EMA"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
Fast Track Designation regulatory
"Orphan Drug and Fast Track Designations from the FDA"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
open-label dose escalation study medical
"a Phase 1b/2a, first-in-human, open-label dose escalation study"
Total operating expenses $14.477 million Compared with $9.803 million in the three months ended September 30, 2025
Research and development expenses $8.618 million Compared with $3.370 million in the three months ended September 30, 2025
General and administrative expenses $5.859 million Compared with $6.433 million in the three months ended September 30, 2025
Net loss $12.925 million Compared with $8.965 million in the three months ended September 30, 2025
Net loss per share ($0.26) per share Compared with ($0.22) per share in the three months ended September 30, 2025
Cash and cash equivalents $176.368 million Compared with $179.972 million at June 30, 2026

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were BNTC's results for the quarter ended September 30, 2026?

Benitec reported a $12.925 million net loss, compared with $8.965 million in the same quarter of 2025. Total operating expenses were $14.477 million, including $8.618 million in research and development and $5.859 million in general and administrative expenses. Cash and cash equivalents were $176.368 million at quarter-end.

What did BNTC report about BB-301's clinical results?

The interim BB-301 results showed a 100% responder rate across all patients in Cohorts 1 and 2, and no serious adverse events had been reported in any patient treated to date. Cohort 1 included six patients who completed 12-month follow-up, while three patients were enrolled in Cohort 2.

When does BNTC's fiscal year change to a calendar year?

Benitec's board approved changing the fiscal year-end from June 30 to December 31, effective November 12, 2026. The transition period runs from July 1 through December 31, 2026, and calendar-year reporting begins with the year commencing January 1, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
--12-310001808898false00018088982026-11-122026-11-12

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2026

 

 

Benitec Biopharma Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39267

84-4620206

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

3940 Trust Way

 

Hayward, California

 

94545

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (510) 780-0819

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001

 

BNTC

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


Item 2.02 Results of Operations and Financial Condition.

On November 13, 2026, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended September 30, 2026 and providing an operational update. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, the information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference into such filing.

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On November 12, 2026, the Board of Directors of the Company approved a resolution changing the Company’s fiscal year-end date from June 30 to December 31 of each calendar year, effective as of the same date.

As a result, the Company will report operating results covering the six-month transition period from July 1, 2026 through December 31, 2026 (the “Transition Period”) in a Transition Report on Form 10-K. Following the Transition Period, the Company will report its operating results on a calendar-year basis, beginning with the fiscal year commencing January 1, 2027 and ending December 31, 2027. Prior to the change in fiscal year end, the Company reported financial results on a fiscal-year basis ending June 30.

The Board approved this change to align the Company’s planning and reporting cycle with the calendar year and to improve comparability of the Company’s operational and financial results.

No amendment to the Company’s Articles of Incorporation or Bylaws was required in connection with this change in fiscal year.


Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release of Benitec Biopharma Inc. dated November 13, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

BENITEC BIOPHARMA INC.

 

 

 

 

Date:

November 13, 2026

By:

/s/ Dr. Jerel A. Banks

 

 

 

Dr. Jerel A. Banks
Chief Executive Officer

 


img183098058_0.gif

Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational Update

•
Positive interim clinical results from the ongoing BB-301 Phase 1b/2a study for dysphagic patients with Oculopharyngeal Muscular Dystrophy (OPMD), presented as a late-breaking poster at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress showed a 100% responder rate across all Cohort 1 (low dose) and Cohort 2 (high dose) patients
•
BB-301 pivotal study design to be finalized in the first calendar quarter of 2027, and the company remains on track to begin the pivotal trial in mid-2027
•
Well-capitalized with cash, as of September 30, 2026, of approximately $176 million
•
Benitec plans to transition its fiscal year-end for financial reporting from June 30 to December 31. In this release, operational and program guidance is presented on a calendar-year (CY) basis, and financial guidance is presented on a June 30 fiscal-year (FY) basis


 

HAYWARD, Calif., Nov.13, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage biotechnology company developing disease-modifying genetic medicines for life-threatening, genetically defined diseases, based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced financial results for its first fiscal quarter ended September 30, 2026, and provided an update on recent clinical data presentations.

“This has been a productive period of continued clinical progress for BB-301,” said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec. “We recently attended ESGCT and presented the interim clinical results for the three patients enrolled in Cohort 2 and the full clinical results for the six patients enrolled in Cohort 1 that have completed the 12-month study follow-up period. The consistency and durability of the clinical benefit observed to date continues to strengthen our conviction in the potential of BB-301 to meaningfully alter the course of OPMD-related dysphagia. We are grateful to the patients, families and investigators who have enabled this progress, and we look forward to confirming the pivotal study design in the first calendar quarter of 2027, with the study on track to commence in mid-2027.”

 

Clinical Highlights

The Company continues to advance BB-301 through clinical development in the ongoing Phase 1b/2a Clinical Study evaluating the safety and clinical efficacy of locally-administered BB-301 for the treatment of OPMD-related dysphagia.

Positive interim clinical results, presented as a late-breaking poster at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress in Hamburg, Germany on October 28, 2026, showed a 100% responder rate across all Cohort 1 (low dose) and Cohort 2 (high dose) patients. There have been no Serious Adverse Events in any patient treated with BB-301 to date.

 

 

 

 

 


img183098058_0.gif

Financial Highlights

First Quarter 2027 FY Financial Results

Total expenses for the quarter ended September 30, 2026, were $14.5 million compared to $9.8 million for the quarter ended September 30, 2025. The Company incurred $8.6 million of research and development expenses compared to $3.4 million for the comparable quarter ended September 30, 2025. Research and development expenses relate primarily to ongoing clinical development of BB-301 for the treatment of OPMD. General and administrative expenses were $5.9 million compared to $6.4 million for the quarter ended September 30, 2025.

Net loss for the quarter ended September 30, 2026, was $12.9 million compared to a loss of $9.0 million for the quarter ended September 30, 2025. Net loss per basic and diluted share was $(0.26) for the quarter ended September 30, 2026 compared to $(0.22) for the quarter ended September 30, 2025. As of September 30, 2026, the Company had $176.5 million in cash and cash equivalents.

Change in Fiscal Year to Calendar Year

The Company also announced today that it plans to change its existing fiscal year-end from June 30 to December 31 commencing with its first periodic report following the Form 10-Q for the fiscal quarter ended September 30, 2026. In this press release, operational and program guidance is presented on a calendar-year (CY) basis, and historical financial guidance is presented on a June 30 fiscal-year (FY) basis.

 

About BB-301

BB-301 is a novel, modified AAV9 capsid expressing a unique, single bifunctional construct promoting co-expression of both codon-optimized Poly-A Binding Protein Nuclear-1 (PABPN1) and two small inhibitory RNAs (siRNAs) against mutant PABPN1 (the causative gene for OPMD). The two siRNAs are modeled into microRNA backbones to silence expression of faulty mutant PABPN1, while allowing expression of the codon-optimized PABPN1 to replace the mutant with a functional version of the protein. BB-301 is administered locally, in a one-time procedure, to the muscles in the throat that drive the swallowing process, an approach designed to maximize local benefit and minimize systemic exposure. We believe the silence and replace mechanism of BB-301 is uniquely positioned for the treatment of OPMD by slowing or halting mutant PABPN1 expression while simultaneously providing a functional replacement protein. BB-301 has received Orphan Drug Designation from the EMA and Orphan Drug and Fast Track Designations from the FDA and is currently being evaluated in a Phase 1b/2a, first-in-human, open-label dose escalation study to evaluate the safety and clinical activity of intramuscular doses of BB-301 administered to subjects with OPMD (NCT06185673).

About Benitec Biopharma Inc.

Benitec Biopharma Inc. (NASDAQ: BNTC) is a clinical-stage biotechnology company developing disease-modifying genetic medicines designed to improve the lives of people with life-threatening, genetically defined diseases. The company’s proprietary “Silence and Replace” DNA-directed RNA interference (ddRNAi) platform combines RNA interference, or RNAi, with gene therapy to create medicines designed to facilitate sustained silencing of disease-causing genes and simultaneous delivery of replacement genes that restore normal cellular function following a single administration. The company’s lead investigational candidate, BB-301, is the first and only disease-modifying genetic medicine in clinical development for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagia. For additional information, visit www.benitec.com.


img183098058_0.gif

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release include forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1993, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Benitec’s plans to develop and commercialize its product candidates, the timing of the completion of preclinical and clinical trials, the timing of the availability of data from our clinical trials, the timing and sufficiency of patient enrollment and dosing in clinical trials, the timing of expected regulatory filings and other regulatory steps, and the clinical utility and potential attributes and benefits of ddRNAi and Benitec’s product candidates, and other forward-looking statements.

These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: the success of our plans to develop and potentially commercialize our product candidates; the timing of the completion of preclinical studies and clinical trials; the timing and sufficiency of patient enrollment and dosing in any future clinical trials; the timing of the availability of data from our clinical trials; the timing and outcome of regulatory filings and approvals; the development of novel adeno-associated viral (AAV) vectors; our potential future out-licenses and collaborations; the plans of licensees of our technology; the clinical utility and potential attributes and benefits of DNA-directed RNA interferences (ddRNAi) and our product candidates, including the potential duration of treatment effects and the potential for a “one shot” cure; our intellectual property position and the duration of our patent portfolio; expenses, ongoing losses, future revenue, capital needs and needs for additional financing, and our ability to access additional financing given market conditions and other factors; the length of time over which we expect our cash and cash equivalents to be sufficient to execute on our business plan; unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the U.S. Food and Drug Administration and other governmental authorities; regulatory developments in the United States of America; our ability to protect and enforce our patents and other intellectual property rights; our dependence on our relationships with our collaboration partners and other third parties; the efficacy or safety of the Company’s products and the products of our collaboration partners; the acceptance of our products and the products of our collaboration partners in the marketplace and market competition; reliance on third-party manufacturers and suppliers, and the risks associated with manufacturing complexity, supply interruptions, and compliance with current good manufacturing practices; sales, marketing and distribution requirements for our product candidates; greater than expected expenses, including expenses relating to litigation or strategic activities; our incurrence of significant losses and the uncertainty of our ability to achieve or sustain profitability or generate any revenue; our ability to satisfy its capital needs through increasing revenue and obtaining additional financing; the impact of local, regional, national and international economic conditions and events, including geopolitical instability, and risks associated with conducting business and seeking regulatory approvals in international markets; our ability to attract and retain key management, scientific, and technical personnel; cyber-security threats and vulnerabilities in our and our third parties' information technology systems; the impact of legislative and regulatory reforms affecting drug pricing and reimbursement, including Medicare drug-price negotiation and government pricing frameworks; potential product liability claims arising from the use of our product candidates in clinical trials or following any future marketing approval; physicians, patients, third-party payers, or others in the medical community may not be receptive to our product candidates, and we may not generate any future revenue from the sale or licensing of our product candidates; and disruptions to U.S. government agency operations, including FDA staffing changes; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission. The Company disclaims any intent or obligation to update these forward-looking statements, except as required by law.

 


img183098058_0.gif

Investor Relations Contact:

Candice Masse

astr partners

candice.masse@astrpartners.com

 

Media Relations Contact:

Audra Friis

Sam Brown Healthcare Communications

(917) 519-9577

audrafriis@sambrown.com

Source: Benitec Biopharma Inc.


img183098058_0.gif

BENITEC BIOPHARMA INC.

Consolidated Balance Sheets

(in thousands, except par value and share amounts)

(Unaudited)

 

 

September 30,
2026

 

 

June 30,
2026

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

176,368

 

 

$

179,972

 

Restricted cash

 

 

114

 

 

 

114

 

Trade and other receivables

 

 

—

 

 

 

4

 

Prepaid and other assets

 

 

1,622

 

 

 

1,595

 

Total current assets

 

 

178,104

 

 

 

181,685

 

Property and equipment, net

 

 

110

 

 

 

178

 

Deposits

 

 

55

 

 

 

55

 

Prepaid and other assets

 

 

244

 

 

 

12

 

Right-of-use assets

 

 

585

 

 

 

693

 

Total assets

 

$

179,098

 

 

$

182,623

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Trade and other payables

 

$

7,962

 

 

$

4,295

 

Accrued employee benefits

 

 

608

 

 

 

553

 

Lease liabilities, current portion

 

 

507

 

 

 

496

 

Total current liabilities

 

 

9,077

 

 

 

5,344

 

Other long-term liabilities

 

 

239

 

 

 

—

 

Lease liabilities, less current portion

 

 

135

 

 

 

266

 

Total liabilities

 

 

9,451

 

 

 

5,610

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.0001 par value—5,000,000 shares authorized; no shares issued or outstanding at September 30, 2026 and June 30, 2026, respectively

 

 

—

 

 

 

—

 

Common stock, $0.0001 par value—160,000,000 shares authorized; 34,889,313 and 34,416,834 shares issued and outstanding at September 30, 2026 and June 30, 2026 respectively

 

 

4

 

 

 

3

 

Additional paid-in capital

 

 

457,237

 

 

 

451,695

 

Accumulated deficit

 

 

(286,647

)

 

 

(273,722

)

Accumulated other comprehensive loss

 

 

(947

)

 

 

(963

)

Total stockholders’ equity

 

 

169,647

 

 

 

177,013

 

Total liabilities and stockholders’ equity

 

$

179,098

 

 

$

182,623

 

 


img183098058_0.gif

BENITEC BIOPHARMA INC.

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

(Unaudited)

 

 

 

Three Months Ended

 

 

September 30,

 

 

2026

 

 

2025

 

Operating expenses:

 

 

 

 

 

 

Research and development

 

 

8,618

 

 

 

3,370

 

General and administrative

 

 

5,859

 

 

 

6,433

 

Total operating expenses

 

 

14,477

 

 

 

9,803

 

Loss from operations

 

 

(14,477

)

 

 

(9,803

)

Other income (loss):

 

 

 

 

 

 

Foreign currency transaction gain (loss)

 

 

(23

)

 

 

(89

)

Interest income, net

 

 

1,576

 

 

 

1,011

 

Other expense, net

 

 

(1

)

 

 

(84

)

Total other income, net

 

 

1,552

 

 

 

838

 

Net loss

 

$

(12,925

)

 

$

(8,965

)

Other comprehensive income:

 

 

 

 

 

 

Unrealized foreign currency translation gain (loss)

 

 

16

 

 

 

89

 

Total other comprehensive income (loss)

 

 

16

 

 

 

89

 

Total comprehensive loss

 

$

(12,909

)

 

$

(8,876

)

Net loss

 

$

(12,925

)

 

$

(8,965

)

Net loss per share:

 

 

 

 

 

 

Basic and diluted

 

$

(0.26

)

 

$

(0.22

)

Weighted average number of shares outstanding:

 

 

 

 

 

 

Basic and diluted

 

 

49,487,369

 

 

 

41,521,280

 

 

 


Filing Exhibits & Attachments

2 documents

Keep reading